Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model

Daptomycin (DAP) is being used more frequently to treat infections caused by vancomycin-resistant enterococcus (VRE). DAP tends to be less active against enterococci than staphylococci and may require high doses or combination therapy to be bactericidal. Fosfomycin (FOF) has activity against VRE and...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Hall Snyder, Ashley D., Werth, Brian J., Nonejuie, Poochit, McRoberts, John P., Pogliano, Joe, Sakoulas, George, Yim, Juwon, Singh, Nivedita, Rybak, Michael J.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2016
Sujets:
Experimental Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5038233/
https://ncbi.nlm.nih.gov/pubmed/27431211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00687-16
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires